Sana Biotechnology, Inc. 8-K

What Happened
Sana Biotechnology, Inc. (SANA) announced on February 17, 2026, that Brian Piper, M.B.A., joined the company as Executive Vice President, Chief Financial Officer, Treasurer, and Principal Financial Officer effective that date. Steven D. Harr, the company's CEO, ceased serving as acting Principal Financial Officer immediately prior to Mr. Piper’s start. The company filed an Offer Letter dated January 27, 2026, and issued a press release announcing the hire.

Key Details

• Start date: February 17, 2026; Offer Letter dated January 27, 2026.
• Cash pay: annual base salary of $515,000 and target annual bonus of 40% of base salary.
• Equity: option to purchase 900,000 shares (10‑year term, exercise price = closing price on grant date) and 200,000 restricted stock units (RSUs). Option vests 25% after 1 year, then 1/48 monthly; RSUs vest 25% per year over 4 years.
• Severance/benefits: if terminated by the company other than for "cause" (or resigns for "good reason") outside the change-in-control protection window, eligible for nine months of severance pay and up to nine months of COBRA health continuation (subject to a general release). Mr. Piper is also eligible to participate in the company’s Change in Control Severance Plan.

Why It Matters
The appointment formalizes Sana’s principal financial officer role with an experienced biotech CFO who has held CFO positions at multiple biopharma companies and managed public-company and IPO experiences. The compensation package combines cash and significant equity grants that align the new CFO’s incentives with shareholder value, while the severance terms provide standard protection for executive transitions. Investors should note potential dilution from the equity awards and that the company has replaced an interim principal financial officer with a permanent CFO.